Refine your search with filters

All-Materials All
Congress-AbstractsCongress Abstracts
Tools-SkillsTools & Skills
PublicationsPublications
Congress-SlidesCongress Presentations
Videos-PodcastsVideos & Podcasts

Quicksearch

P706: A distinct subset of tissue-resident Th17 cells expands in the inflamed intestines of Crohn’s Disease patients and responds to colitogenic bacteriaECCO'22
Year: 2022
Authors: ParoniPhD, M.(1);Leccese, G.(1);Ranzani, V.(2);Pagani, M.(3);Landini, P.(1);Vecchi, M.(4);Abrignani, S.(2);Facciotti, F.(5);Caprioli, F.(4);Geginat, J.(2);
(1)University of Milan, Department of Biosciences, Milano, Italy;(2)INGM-National Institute of Molecular Genetics “Romeo ed Enrica Invernizzi”, INGM-National Institute of Molecular Genetics “Romeo ed Enrica Invernizzi”, Milano, Italy;(3)FIRC Institute of Molecular Oncology IFOM- 20139 Milan- Italy, FIRC Institute of Molecular Oncology IFOM- 20139 Milan- Italy, Milano, Italy;(4)Gastroenterology and Endoscopy Unit- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Gastroenterology and Endoscopy Unit- Fondazione IRCCS Ca’ Granda Ospedale Maggiore Policlinico, Milano, Italy;(5)Department of Experimental Oncology- European Institute of Oncology-, Department of Experimental Oncology- European Institute of Oncology-, Milano, Italy;
P707: Microbial signature of the colon is not associated with response to vedolizumab in Crohn’s diseaseECCO'22
Year: 2022
Authors: HagemanMD, I.(1,2);Joustra, V.(1);Li Yim, A.(2,3);Davids, M.(4);Henneman, P.(3);Hakvoort, T.(2);Probert, F.(5);Satsangi, J.(6);D'Haens, G.(1);De Jonge, W.(2);
(1)Amsterdam UMC- University of Amsterdam, Department of Gastroenterology & Hepatology, Amsterdam, The Netherlands;(2)Amsterdam UMC- University of Amsterdam, Tytgat institute for for Liver and Intestinal Research, Amsterdam, The Netherlands;(3)Amsterdam UMC- University of Amsterdam, Genome Diagnostics Laboratory- Department of Human Genetics, Amsterdam, The Netherlands;(4)Amsterdam UMC- University of Amsterdam, Laboratory of Experimental Vascular Medicine- Academic Medical Center, Amsterdam, The Netherlands;(5)Oxford University, Department of Chemistry- Chemistry Research Laboratory- Mansfield Road, Oxford, United Kingdom;(6)Oxford University, Translational Gastroenterology Unit- NIHR Oxford Biomedical Research Centre- Oxford University Hospitals NHS Foundation Trust, Oxford, United Kingdom;On behalf of the EPIC-Pioneer consortium
P708: Ileal involvement defined by Montreal classification in Crohn’s disease is associated with a distinct microbial composition in ileal and colonic mucosaECCO'22
Year: 2022
Authors: Hernandez-Rocha, C.(1);Nayeri, S.(1);Turpin, W.(1);Borowski, K.(1);Stempak, J.(1);Silverberg, M.S.(1);
(1)Zane Cohen Centre for Digestive Diseases, Lunenfeld-Tanenbaum Research Institute- Sinai Health System, Toronto, Canada;
P709: Distinct Pattern of Gut Microbial Dysbiosis in Crohn's Disease and Intestinal Tuberculosis - A Machine Learning-based classification modelECCO'22
Year: 2022
Authors: Markandey, M.(1);Bajaj, A.(1);Vuyyuru, S.K.(1);Mohta, S.(1);Singh, M.(1);Verma, M.(1);Kumar, S.(1);Kante, B.(1);Kumar, P.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;
P710: Evaluation of helminth extracellular vesicles as a novel therapeutic for inflammatory bowel disease in murine models of colitisECCO'22
Year: 2022
Authors: Bray, G.(1);
(1)James Cook University, Australian Institute of tropical health and medicine, Cairns, Australia;P. Giacomin
P711: Stool microbiome communities predict remission in pediatric Crohn’s disease patients even after start of treatmentECCO'22
Year: 2022
Authors: VerburgtMD, C.(1);Dunn, K.A.(2);Bielawski, J.P.(3);Otley, A.R.(4);Heyman, M.B.(5);Sunseri, W.(6);Shouval, D.(7);Levine, A.(8);de Meij, T.(1);Hyams, J.S.(9);Denson, L.A.(10);Kugathasan, S.(11);Benninga, M.A.(1);de Jonge, W.J.(12);Van Limbergen, J.E.(1);
(1)Emma Children’s Hospital- Amsterdam University Medical Centres, Department of Paediatric Gastroenterology and Nutrition, Amsterdam, The Netherlands;(2)Dalhousie university, Department of Biology, Halifax, Canada;(3)Dalhousie university, Department of Mathematics and Statistics, Halifax, Canada;(4)Dalhousie university, Department of Paediatrics, Halifax, Canada;(5)Department of Paediatrics, UCSF Benioff Children’s Hospital- University of California, San Francisco, United States;(6)UPMC Children’s Hospital of Pittsburgh, Department of Paediatrics, Pittsburgh, United States;(7)Schneider Children’s Medical Center of Israel, Institute of Gastroenterology- Nutrition and Liver Diseases, Petah Tikva, Israel;(8)Wolfson Medical Centre- Holon- Israel- Sackler School of Medicine- Tel Aviv University, Paediatric Gastroenterology and Nutrition Unit, Tel Aviv, Israel;(9)Connecticut Children’s Medical Center, Division of Digestive Diseases- Hepatology and Nutrition, Hartford, United States;(10)Cincinatti Children's Hospital Medical Center and the University of Cincinnati College of Medicine, Department of Paediatrics, Cincinnati, United States;(11)Emory University, Department of Paediatrics, Atlanta, United States;(12)Amsterdam University Medical Centers- University of Amsterdam, Tytgat Institute for Liver and Intestinal Research- Amsterdam Gastroenterology Endocrinology and Metabolism, Amsterdam, The Netherlands;
P712: Fungal microbiota composition in Inflammatory Bowel Disease patients in a Norwegian cohort: characterization of disease phenotypes and correlation with clinical activity and disease course.ECCO'22
Year: 2022
Authors: Catalàn-Serrax, I.(1,2,3);Thorsvik, S.(3,4);Beisvag, V.(2);Bruland, T.(2);Underhill, D.(3,5,6);Sandvik, A.K.(2,3,4);Van Beelen Granlund, A.(2,3,4);
(1)Levanger Hospital- Nord-Trøndelag Hospital Trust- Department of Medicine- Gastroenterology- Levanger- Norway., Department of Gastroenterology, Trondheim, Spain;(2)Norwegian University of Science and Technology, Department of Clinical and Molecular Medicine, Trondheim, Norway;(3)Norwegian University of Science and Technology- Centre for Molecular Inflammation Research CEMIR- Trondheim- Norway., Department of Clinical and Molecular Medicine, Trondheim, Norway;(4)St Olav’s Hospital, Gastroenterology, Trondheim, Norway;(5)Cedars-Sinai Medical Center, F. Widjaja Foundation Inflammatory Bowel and Immunobiology Research Institute, Los Angeles, United States;(6)Cedars-Sinai Medical Center, Research Division of Immunology, Los Angeles, United States;Inflammatory Bowel Disease Research Group. NTNU
P713: Gut microbiota alterations after bowel preparation amongst inflammatory bowel disease patientsECCO'22
Year: 2022
Authors: Rutka, M.(1);Szántó, K.(1);Bacsur, P.(1);Resál, T.(1);Jójárt, B.(2);Bálint, A.(1);Ari, E.(3);Kintses, B.(4);Fehér, T.(4);Asbóth, A.(5);Pigniczki, D.(1);Bor, R.(1);Fábián, A.(1);Farkas, K.(1);Maléth, J.(2);Szepes, Z.(1);Molnár, T.(1);
(1)Szent-Györgyi Albert Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(2)Hungarian Academy of Science- University of Szeged, Momentum Epithelial Cell Signaling and Secretion Research Group, Szeged, Hungary;(3)Institute of Biochemistry- Biological Research Centre, Synthetic and Systems Biology Unit, Szeged, Hungary;(4)Hungarian Centre of Excellence of Molecular Medicine- University of Szeged, Translational Microbiology Research Group, Szeged, Hungary;(5)Eötvös Lóránd University, Department of Genetics, Budapest, Hungary;
P714: Comparison of intestinal microbiota profiles of faecal samples, rectal swabs and mucosal biopsies in patients with Inflammatory Bowel Disease. A multicentre, observational study.ECCO'22
Year: 2022
Authors: Van Rossen, T.(1);van den Hoek, K.(2);Budding, A.(3);van Bodegraven, A.(4);
(1)Amsterdam UMC, Medical Microbiology & Infection Control, Amsterdam, The Netherlands;(2)Amsterdam UMC, Gastroenterology & Hepatology, Amsterdam, The Netherlands;(3)inBiome, inBiome, Amsterdam, The Netherlands;(4)Zuyderland Medical Center, Gastroenterology & Hepatology, Sittard-Geleen, The Netherlands;
P716: Exclusive Enteral Nutrition refurbishes beneficial gut microbiota in patients with Acute Severe Ulcerative ColitisECCO'22
Year: 2022
Authors: Bajaj, A.(1);Markandey, M.(1);Sahu, P.(1);Vuyyuru, S.K.(1);Kante, B.(1);Kumar, P.(1);Singh, N.(1);Gupta, A.(1);Singh, M.(1);Verma, M.(1);Makharia, G.(1);Kedia, S.(1);Ahuja, V.(1);
(1)All India Institute of Medical Sciences, Department of Gastroenterology and Human Nutrition, New Delhi, India;
P717: Faecal Microbiota Transplant in Ulcerative Colitis (FMTUC) – A randomised clinical trial feasibility studyECCO'22
Year: 2022
Authors: Jitsumura, M.(1,2);Cunningham , A.(1);Hitchings, M.D.(3);Wilkinson, T.(3);Kinross, J.(4);Row, P.(5);Davies, A.(6);Dean Anthony, H.(1);
(1)Singleton Hospital, Department of Colorectal Surgery, Swansea, United Kingdom;(2)Poole Hospital, General Surgery, Poole, United Kingdom;(3)Swansea University Medical School, Medical Microbiology and Infectious Diseases, Swansea, United Kingdom;(4)St. Mary's Hospital- Imperial College London, Department of Surgery and Cancer, London, United Kingdom;(5)Swansea University Medical School, Biochemistry Group, Swansea, United Kingdom;(6)Swansea University Medical School- Singleton Hospital, Public Health Wales Microbiology, Swansea, United Kingdom;
P718: Characterization of microbiota and metabolomic profile in human colonic surgical resections of UC patientsECCO'22
Year: 2022
Authors: Bauset, C.(1);Carda-Diéguez, M.(2);Buetas, E.(2);Lis-López, L.(1);Navarro, F.(3);Ortiz-Masiá, D.(4);Calatayud, S.(1);Barrachina, M.D.(1);Mira, Á.(2);Cosín-Roger, J.(5);
(1)Universitat de Valencia, Pharmacology, Valencia, Spain;(2)FISABIO, Genomics and Health Department, Valencia, Spain;(3)Hospital de Manises, Colorectal surgery, Valencia, Spain;(4)Universitat de Valencia, Medicine, Valencia, Spain;(5)FISABIO, Unidad Mixta Facultad de Medicina-Hospital Dr. Peset, Valencia, Spain;
P719: Identification of differentially expressed genes between AIEC and non-AIEC clinical isolates during in vitro cell infectionECCO'22
Year: 2022
Authors: Bonet Rossinyol, Q.(1);Camprubí-Font, C.(1);Lopez-Siles, M.(1);Martinez-Medina, M.(1);
(1)Universitat de Girona, Biology, Girona, Spain;Microbiology of Intestinal Diseases Research Group
P720: Similar risk of infection with SARS-CoV-2 in immunocompromised and immunocompetent patients with inflammatory bowel disease and healthy controlsECCO'22
Year: 2022
Authors: Kante, B.(1);Vuyyuru, S.K.(1);Gupta, R.(2);Dwivedi, T.(2);Kumar, P.(1);Mundhra, S.(1);Golla, R.(1);Virmani, S.(1);Verma, M.(1);Makharia, G.(1);Ahuja, V.(1);Kedia, S.(1);
(1)AIIMS, Gastroenterology, NEW DELHI, India;(2)AIIMS, Lab Oncology, New Delhi, India;
P721: Faecal microbiota analysis with body composition and nutritional habits simultaneously amongst Crohn’s disease patientsECCO'22
Year: 2022
Authors: Bálint, A.(1);Bacsur, P.(1);Resál, T.(1);Jójárt, B.(2);Gyuris, Z.(3);Jaksa, G.(3);Pintér, L.(3);Takács, B.(4);Pál, S.(5);Gácser, A.(5);Szántó, K.J.(1);Rutka, M.(1);Bor, R.(1);Fábián, A.(1);Farkas, K.(1);Maléth, J.(2);Szepes, Z.(1);Molnár, T.(1);
(1)Szent-Györgyi Albert Medical School- University of Szeged, Department of Medicine, Szeged, Hungary;(2)Hungarian Academy of Science- University of Szeged, Momentum Epithelial Cell Signaling and Secretion Research Group, Szeged, Hungary;(3)Delta Bio 2000 Ltd., Delta Bio 2000 Ltd., Szeged, Hungary;(4)Hungarian Centre of Excellence of Molecular Medicine- University of Szeged, Mutagenesis and Carcinogenesis Research Group, Szeged, Hungary;(5)Hungarian Centre of Excellence of Molecular Medicine- University of Szeged, Pathogen Fungi Research Group, Szeged, Hungary;
P722: Compositional differences of gut microbiome using taxonomic profiling in patients with ulcerative colitis after treatment with vedolizumabECCO'22
Year: 2022
Authors: Yoon, A.(1,2,3);Kim, K.(1);Oh, K.(1);Kim, E.S.(4);Kim, E.H.(4);Kim, S.(5);Jeong, J.Y.(4);Kweon, M.N.(5);Hwang, S.W.(1,3);Park, S.H.(1,3);Myung, S.J.(1);Yang, S.K.(1,3);Ye, B.D.(1,3);
(1)University of Ulsan College of Medicine- Asan Medical Center, Department of Gastroenterology, Seoul, Korea- Republic Of;(2)Asan Medical Institute of Convergence Science and Technology- University of Ulsan College of Medicine- Asan Medical Center, Department of Medical Science, seoul, Korea- Republic Of;(3)University of Ulsan College of Medicine- Asan Medical Center, Inflammatory Bowel Disease Center, seoul, Korea- Republic Of;(4)University of Ulsan College of Medicine- Asan Medical Center, Department of Convergence Medicine and Asan Institute for Life Sciences, seoul, Korea- Republic Of;(5)University of Ulsan College of Medicine- Asan Medical Center, Mucosal Immunology Laboratory- Department of Convergence Medicine, seoul, Korea- Republic Of;
DOP01: Efficacy and safety of the IL-6 trans-signalling inhibitor olamkicept: a phase 2 randomized, placebo-controlled trial in moderately to severely active Ulcerative ColitisECCO'21 Virtual
Year: 2021
Authors: Chen, B.(1);Zhang, S.(1);Wang, B.(2);Chen, H.(3);Li, Y.(4);Cao, Q.(5);Zhong, J.(6);Xie, M.(7);Ran, Z.(8);Tang, T.(9);Yang, M.(10);Guo, T.(10);Xu, B.(10);Cai, Z.(10);Schreiber, S.(11);Chen, M.(1);
(1)The First Affiliated Hospital of Sun Yat-sen University, gastroenterology department, Guangzhou, China;(2)Tianjin Medical University General Hospital, gastroenterology department, Tianjin, China;(3)Zhongda Hospital Affiliated to Southeast University, gastroenterology department, Nanjing, China;(4)Shengjing Hospital affiliated to China Medical University, gastroenterology department, Shenyang, China;(5)Run Run Shaw Hospital Affiliated to Zhejiang University School of Medicine, gastroenterology department, Hangzhou, China;(6)Ruijin Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, gastroenterology department, Shanghai, China;(7)National Taiwan University Hospital, gastroenterology department, Taibei, China;(8)Renji Hospital Affiliated to Shanghai Jiao Tong University School of Medicine, gastroenterology department, Shanghai, China;(9)The First Hospital of Jilin University, gastroenterology department, Changchun, China;(10)I-Mab Biopharma, Research and Development, Shanghai, China;(11)University Hospital Schleswig-Holstein, Department Medicine I, Kiel, Germany
DOP02: αEβ7 positive γδ T cells are associated with mucosal healing in Ulcerative Colitis and have a homeostatic immunophenotypeECCO'21 Virtual
Year: 2021
Authors: Dart, R.(1,2);Zlatareva, I.(1,2);Irving, P.(1,3);Hayday, A.(1,2)
(1)King's College London, Peter Gorer Department of Immunobiology, London, United Kingdom;(2)Francis Crick Institute, Immunosurveillance Lab, London, United Kingdom;(3)Guy's and St Thomas Hospital, Department of Gastroenterology, London, United Kingdom
DOP03: Early change in epithelial neutrophilic infiltrate predicts long-term response to biologics in Ulcerative ColitisECCO'21 Virtual
Year: 2021
Authors: Narula, N.(1);Wong, E.(1);Colombel, J.F.(2);Riddell, R.(3);Marshall, J.(4);Reinisch, W.(5);Dulai, P.(6)
(1)McMaster University, Department of Medicine- Division of Gastroenterology, Hamilton, Canada;(2)Icahn School of Medicine at Mount Sinai, Division of Gastroenterology, New York, United States;(3)Mount Sinai Hospital, Department of Pathology and Laboratory Medicine, Toronto, Canada;(4)McMaster University, Department of Gastroenterology, Hamilton, Canada;(5)Medical University of Vienna, Department of Internal Medicine III- Division of Gastroenterology and Hepatology, Vienna, Austria;(6)University of California San Diego, Division of Gastroenterology, La Jolla, United States